Charles River Laboratories International, Inc. (CRL)
Health Care · Life Sciences Tools & Services · US stock · price as of 16 Oct 2026
Key indicators
Price
$300.15
52-week range
$146.20 – $333.30
Market cap
$14.4B
P/E (trailing)
–
EV / EBITDA
43.4×
Free-cash-flow yield
2.6%
Dividend yield
–
Revenue (last 12 months)
$4.0B
Revenue growth (3y a year)
0.3%
Operating margin
2.3%
Return on invested capital
1.4%
Net debt / EBITDA
6.3×
Fair value
Blended fair value$168.66 range $169 – $169
Versus priceOvervalued−44% to fair value
Peer multiples
$168.66
10-year DCF (market-scaled)
n/m
Earnings power value (floor, not blended)
$24.84
Model uncertainty
Medium
X-Ray Score
22/ 100 · Medium confidence · ahead of 2% of sector peers
Valuation15
Growth23
Profitability33
Financial health14
Dividends–
Five-year price chart navy: price · brown: 200-day average · blue band: fair value range
Executive summary
Charles River Laboratories supports drug development with research models, preclinical services and manufacturing support. It breeds laboratory research animals, carries out discovery and safety assessment studies for drug candidates, and supplies testing and related services for the manufacture of biologic products. Customers are pharmaceutical and biotechnology companies, along with academic and government researchers. The business is organised into groups for research models, discovery and safety assessment, and manufacturing solutions.
Revenue of $4.0 billion over the last twelve months comes from research models and from fees for contract research and testing work. Revenue has grown at 0.3% a year across the last three years. The operating margin is 2.3%, the business earns 1% on the capital invested in it, and net debt is 6.3 times EBITDA. No dividend is paid.
StocksXray gives Charles River Laboratories International, Inc. an X-Ray Score of 22 out of 100 (medium confidence), ahead of 2% of the S&P 500 stocks in its sector. Its strongest lens is profitability (33) and its weakest is financial health (14).
Our fair value blend is $168.66 (range $168.66 to $168.66). At $300.15 the stock trades 78% above that blend, so the label is "Overvalued" with medium model uncertainty. Fair value is a range, not a price target.
XStocksXray
Charles River Laboratories International, Inc. (CRL)
Valuation history multiples at each fiscal year-end price; the last column uses today's price and the last twelve months
FY2021
FY2022
FY2023
FY2024
FY2025
Now
Price
$369.20
$217.90
$236.40
$186.16
$203.66
$300.15
Market cap
$19.0B
$11.2B
$12.2B
$9.6B
$10.1B
$14.4B
P/E
48.6×
23.0×
25.6×
930.8×
–
–
EV / revenue
6.0×
3.4×
3.5×
2.9×
3.0×
4.2×
EV / EBITDA
25.0×
14.3×
15.6×
19.8×
28.1×
43.4×
Price / free cash flow
35.7×
37.9×
33.3×
19.2×
19.5×
38.9×
Free-cash-flow yield
2.8%
2.6%
3.0%
5.2%
5.1%
2.6%
Price / book
7.5×
3.8×
3.4×
2.8×
3.2×
5.1×
Dividend yield
–
–
–
–
–
–
Fundamentals checklist ● 2 Good · ● 1 Average · ● 11 Bad · each check graded against the sector
Cash quality
Earnings backed by cash−10.9%Good
Free-cash-flow yield2.6%Bad
Risk models
Altman Z score1.7×Bad
Piotroski F-Score4 of 9Bad
Growth
Free-cash-flow growth (3y)20.7%Good
Revenue growth (3y)0.3%Bad
Growth consistency20%Bad
Balance sheet
Current ratio1.3×Average
Net debt / EBITDA6.3×Bad
Interest cover0.8×Bad
Valuation
Fair value vs price0.6×Bad
EBIT / EV yield0.5%Bad
Profitability
Return on invested capital1.4%Bad
Operating margin2.3%Bad
XStocksXray
Charles River Laboratories International, Inc. (CRL)
Financials US$ millions, from SEC filings; last column is the last twelve months
Income statement
FY21
FY22
FY23
FY24
FY25
LTM
Revenue
3,540
3,976
4,129
4,050
4,015
3,999
Gross profit
–
–
–
–
–
–
Operating income
590
651
617
227
25
90
Net income
391
486
475
22
-144
-238
Diluted EPS ($)
7.60
9.48
9.22
0.20
-2.91
-4.87
Free cash flow
532
295
365
502
518
371
Gross margin
–
–
–
–
–
–
Operating margin
16.7%
16.4%
14.9%
5.6%
0.6%
2.3%
Net margin
11.0%
12.2%
11.5%
0.5%
−3.6%
−6.0%
Balance sheet
FY21
FY22
FY23
FY24
FY25
LTM
Total assets
7,024
7,603
8,195
7,528
7,135
7,532
Cash
241
234
277
195
214
192
Total debt
2,664
2,709
2,650
2,240
2,137
2,625
Equity
2,535
2,976
3,597
3,462
3,165
2,840
Dividend per share ($)
–
–
–
–
–
–
Revenue and net income US$ billions: navy revenue, teal net income
Margins blue gross, teal operating, brown net
Latest quarters
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue ($M)
984
1,032
1,005
994
996
1,004
Growth vs a year earlier
−2.7%
+0.6%
−0.5%
−0.8%
+1.2%
−2.7%
Net income ($M)
25
52
54
-277
-15
-1
Diluted EPS ($)
0.50
1.06
1.10
–
-0.30
-0.03
XStocksXray
Charles River Laboratories International, Inc. (CRL)
Every number comes from SEC filings, end-of-day prices and the StocksXray models described on the methodology page. The X-Ray Score ranks each metric against the company's own sector. Fair value blends three models and carries a typical error of about 40%, so treat it as a range. Analyst ratings, price targets and earnings-call summaries are not part of this report. Educational research, not financial advice; read the disclaimer.